The Pharma Data

DECEMBER 18, 2020

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer. Food and Drug Administration (FDA) has approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. BASEL, Switzerland, Dec.

Hormones 52

Hormones FDA Approval Containment Medicine 52

The Pharma Data

SEPTEMBER 1, 2021

The FDA approval of INVEGA HAFYERA™ is based on the results of a 12-month, randomized, double-blind, non-inferiority Phase 3 global study that enrolled 702 adults (ages 18-70) living with schizophrenia from 20 countries. DFAPA, Medical Director at ATP Clinical Research and 6-month paliperidone palmitate clinical trial investigator.

FDA Approval 52

FDA Approval Medicine Clinical Trials Clinical Trials 52

pharmaphorum

AUGUST 8, 2022

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ($3.1 billion) blockbuster. Most men with mHSPC will eventually progress to CRPC, which has poor survival prospects.

Sales 57

Sales Hormones FDA Approval Marketing 57

pharmaphorum

OCTOBER 26, 2022

Food and Drug Administration approved Vtama (tapinarof) cream, an aryl hydrocarbon receptor agonist and the first FDA-approved steroid-free topical medication in its class. Two months later, Arcutis won approval for its Zoryve (roflumilast) cream. When this hormone is suppressed, response to stressors (e.g.

Hormones 98

Hormones FDA Approval Doctors Doctor 98

XTalks

MARCH 15, 2023

FDA-approved ADHD-specific non-stimulants are a relatively newer class of medication designed to treat ADHD that have much fewer side effects than stimulants. Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations.

Drugs 98

Drugs Sales Trials Marketing 98

XTalks

NOVEMBER 9, 2022

Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. Lilly is also working towards an obesity treatment form of tirzepatide, with trials currently underway to evaluate its weight loss effects. The obesity drug market is currently valued at $2.82 billion in 2021 to $61.6

Insulin 98

Insulin Hormones FDA Approval Sales 98

Intouch Solutions

AUGUST 5, 2021

For trans individuals, years may pass between doctor visits because of the emotional and financial tolls that can accompany them. Aside from being casually misgendered by office staff, she was eventually placed with a doctor that had working knowledge of trans needs, but even then, experienced hurdles.

Marketing 52

Marketing Doctors Doctor Clinical Trials 52